106 related articles for article (PubMed ID: 17068619)
1. [The inhibitory effect of paclitaxel nanoparticles on ovarian cancer xenografts and lymphatic targeting].
Lu HX; Xu CJ; Li B; Kang Y; Huang Q; Li LM; Chen QH
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):483-6. PubMed ID: 17068619
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
[TBL] [Abstract][Full Text] [Related]
3. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Tong L; Chen W; Wu J; Li H
Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect and toxicity of Lipusu in rat ovarian cancer xenografts.
Ye L; He J; Hu Z; Dong Q; Wang H; Fu F; Tian J
Food Chem Toxicol; 2013 Feb; 52():200-6. PubMed ID: 23149094
[TBL] [Abstract][Full Text] [Related]
5. pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice.
Dalela M; Shrivastav TG; Kharbanda S; Singh H
ACS Appl Mater Interfaces; 2015 Dec; 7(48):26530-48. PubMed ID: 26528585
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
Sui M; Chen F; Chen Z; Fan W
Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine-based amphiphilic block copolymer micelles as a biocompatible, drug delivery carrier for treatment of human hepatocellular carcinoma with paclitaxel.
Miyata R; Ueda M; Jinno H; Konno T; Ishihara K; Ando N; Kitagawa Y
Int J Cancer; 2009 May; 124(10):2460-7. PubMed ID: 19173297
[TBL] [Abstract][Full Text] [Related]
8. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of carbon nanoparticle-paclitaxel suspension for use in intraperitoneal chemotherapy.
Cai Y; Zhang X
Hepatogastroenterology; 2013; 60(128):1998-2003. PubMed ID: 24719940
[TBL] [Abstract][Full Text] [Related]
10. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
[TBL] [Abstract][Full Text] [Related]
11. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable Paclitaxel colloids controls lymphatic metastasis in lung cancer.
Liu J; Meisner D; Kwong E; Wu XY; Johnston MR
Cancer Res; 2009 Feb; 69(3):1174-81. PubMed ID: 19176391
[TBL] [Abstract][Full Text] [Related]
12. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice.
Cirstoiu-Hapca A; Buchegger F; Lange N; Bossy L; Gurny R; Delie F
J Control Release; 2010 Jun; 144(3):324-31. PubMed ID: 20219607
[TBL] [Abstract][Full Text] [Related]
13. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions.
Mohamed F; Marchettini P; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2003 Nov; 52(5):405-10. PubMed ID: 12879282
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer.
Devalapally H; Duan Z; Seiden MV; Amiji MM
Int J Cancer; 2007 Oct; 121(8):1830-8. PubMed ID: 17557285
[TBL] [Abstract][Full Text] [Related]
16. Enhanced drug-loading and therapeutic efficacy of hydrotropic oligomer-conjugated glycol chitosan nanoparticles for tumor-targeted paclitaxel delivery.
Koo H; Min KH; Lee SC; Park JH; Park K; Jeong SY; Choi K; Kwon IC; Kim K
J Control Release; 2013 Dec; 172(3):823-31. PubMed ID: 24035978
[TBL] [Abstract][Full Text] [Related]
17. A targeting drug delivery system for ovarian carcinoma: transferrin modified lipid coated paclitaxel-loaded nanoparticles.
Li R; Zhang Q; Wang XY; Chen XG; He YX; Yang WY; Yang X
Drug Res (Stuttg); 2014 Oct; 64(10):541-7. PubMed ID: 24443309
[TBL] [Abstract][Full Text] [Related]
18. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer.
Vassileva V; Allen CJ; Piquette-Miller M
Mol Cancer Ther; 2008 Mar; 7(3):630-7. PubMed ID: 18347149
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.
Hou WJ; Guan JH; Dong Q; Han YH; Zhang R
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice.
Zhang ZM; Yang XY; Deng SH; Xu W; Gao HQ
Chin Med J (Engl); 2007 Aug; 120(15):1336-42. PubMed ID: 17711740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
